What We're Reading: Page 314
Industry reads hand-picked by our editors
Sep 07, 2016
-
Xconomy
With new name and $47M, Proclara begins first big Alzheimer's test
-
The Street
Retrophin (with help from Martin Shkreli) advances drug for rare kidney disease
-
Stat
Doctors Without Borders urges Gilead to rethink its hepatitis C strategy in Ukraine
-
Endpoints
Moderna blueprints $100M facility, plans to double the pipeline after a $474M megaround
Sep 06, 2016
-
Vanity Fair
How Elizabeth Holmes's house of cards came tumbling down
-
Bloomberg
Drug industry group starts ad campaign to push back on pricing
-
Wall Street Journal
New drugs for ovarian cancer patients
-
The Hill
EpiPen maker feels heat from Congress
-
Reuters
Danaher to buy Cepheid in $4 billion deal to expand in diagnostics
Sep 02, 2016
-
Endpoints
Novartis’ retreat on CAR-T includes axing most of its senior execs on the team
-
Washington Post
For a 6-year-old with cancer, a future staked on medicine’s hottest field
-
New York Times
Hillary Clinton to unveil plan to address 'excessive' increases in drug prices
-
Reuters
What do patients know about generic biotech drugs?
Sep 01, 2016
-
Wall Street Journal
EpiPen Maker Mylan Tied Executive Pay to Aggressive Profit Targets
-
Financial Times
Biogen predicts preventive drug for Alzheimer's disease
-
San Diego Tribune
UCSD Nobel laureate Roger Tsien dies
-
Stat
Long Island county sues opioid drug makers for misleading marketing
Previous
